Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 2

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Dermatologic 1

Conditions

Prostatic Neoplasms 2Melanoma 1Carcinoma, Renal Cell 1

Interventions

Specimen Handling 329Magnetic Resonance Spectroscopy 238Biopsy 196Nivolumab 57Cyclophosphamide 52X-Rays 49Radiation 47Paclitaxel 47Carboplatin 47Cisplatin 46pembrolizumab 45Taxes 45Immunoglobulin G 45Disulfides 45Platinum 421,2-diaminocyclohexaneplatinum II citrate 42Radiotherapy 38Doxorubicin 36Ipilimumab 32Gemcitabine 32atezolizumab 31CTLA-4 Antigen 31olaparib 28fludarabine 27venetoclax 25Vincristine 25Bevacizumab 25Prednisone 24cabozantinib 23Phantoms, Imaging 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × MK 2206 × 90 days × Clear all
NCT01251861 2026-05-29

Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
108 enrolled 16 charts
Genitourinary

Prostatic Neoplasms

NCT01480154 2026-04-13

Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
62 enrolled
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡